SOURCE: MIV Therapeutics, Inc.

October 21, 2008 09:53 ET

Update: JACC Intervention Publishes MIV's VESTASYNC I Trial Preliminary Results

ATLANTA, GA--(Marketwire - October 21, 2008) - MIV Therapeutics, Inc. (OTCBB: MIVI) (FRANKFURT: MIVN), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that the Journal of the American College of Cardiology Intervention (JACC Intervention) published preliminary results from the VESTASYNC I trial. The peer-reviewed article titled "Preliminary Results of the Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting Stent for the Treatment of Single De Novo Coronary Lesions - A First-In-Human Analysis of a Third Generation Drug-Eluting Stent (DES) System" appears in the October 21st edition of JACC and is available online at

Dr. Mark Landy, MIV President and Chief Executive Officer, said, "The publication of the preliminary VESTASYNC I trial results in such a prestigious, peer-reviewed journal as JACC is clearly a vote of confidence in the soundness of our science. We are very proud to be included and to receive this tremendous recognition by the scientific community."

The article, authored by J. Ribamar Costa, Jr., M.D. et al., describes the positive results from the four-month follow-up of a multicenter, 15-patient, First-In-Man study led by principal investigator Alexandre Abizaid, M.D., Ph.D., Chief of Coronary Intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. The VESTAsync™ drug-eluting stent was successfully implanted in all cases, and there were no procedure and in-hospital complications. Life-long aspirin and five-month clopidogrel therapy were prescribed for all patients. At four months, in-stent late lumen loss was 0.30 +/- 0.25 mm and percent of stent obstruction was 2.8 +/- 2.2%. The VESTAsync™ drug-eluting stent late loss of 0.30 mm situates this new device among the highest-efficacy DES, with the advantage of a polymer-free system using less drug than first-generation equivalents. After up to six months of clinical follow-up, no major adverse cardiac events were registered.

At the Transcatheter Cardiovascular Therapeutics (TCT) conference last year in October 2007, Dr. Abizaid presented four-month follow-up efficacy data on 13 patients in the 15-patient study. The Company has since reported excellent data at 12-months clinical follow up on all 15 patients.

MIV Therapeutics is currently in a pivotal trial for VESTAsync™, the company's polymer-free drug-eluting stent. The VESTASYNC II trial is a 120 randomized controlled study designed to demonstrate the safety and efficacy of the VESTAsync™ where patients are given anti-platelet medication (Plavix) for only three months. The current anti-platelet standard is a minimum duration of one year and in many cases is life-long therapy.

About MIV Therapeutics

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV's inventions in the global marketplace. For more information, please visit

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. All statements that discuss expectations and projections with respect to future matters including, without limitation, statements relating to the safety and efficacy of the Company's product and the ability of the Company's product to rejuvenate the stent market are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, market acceptance of the Company's product, the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated, and other factors identified in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's annual report on Form 10-K for the year ended May 31, 2007 and Forms 10-Q. The Company expressly disclaims any obligation to update publicly or otherwise revise these statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Contact Information